<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etiology of hypocalcemia in infants and children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etiology of hypocalcemia in infants and children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Etiology of hypocalcemia in infants and children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Carpenter, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A narrow range of extracellular calcium concentrations provides for cell stability and survival and is maintained by an intricate homeostatic system. The etiology of hypocalcemia can be related to failure of a component of this system, such as deficiency of or resistance to parathyroid hormone (PTH) or vitamin D, or a defect of the calcium-sensing receptor (CaSR).</p><p>The etiology and pathogenesis of hypocalcemia in the infant and child and a brief summary of calcium homeostasis will be presented here. An approach to determining the cause of hypocalcemia is presented separately. (See  <a class="medical medical_review" href="/d/html/837.html" rel="external">"Diagnostic approach to hypocalcemia"</a>.)</p><p>Treatment of hypocalcemia is covered in the following topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypocalcemia due to hypoparathyroidism (see  <a class="medical medical_review" href="/d/html/99737.html" rel="external">"Hypoparathyroidism"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypocalcemia in neonates (see  <a class="medical medical_review" href="/d/html/5060.html" rel="external">"Neonatal hypocalcemia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypocalcemia due to vitamin D deficiency (see  <a class="medical medical_review" href="/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe acute and/or symptomatic hypocalcemia (carpopedal spasm, tetany, seizures) (see  <a class="medical medical_review" href="/d/html/826.html" rel="external">"Treatment of hypocalcemia", section on 'Severe symptomatic and/or acute hypocalcemia'</a> and  <a class="medical medical_review" href="/d/html/6386.html" rel="external">"Primary drugs in pediatric resuscitation", section on 'Calcium'</a>)</p><p></p><p class="headingAnchor" id="H5022538"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Physiologic hypocalcemia refers to a reduction in the concentration of ionized calcium in serum or whole blood. Measurements of ionized calcium and total calcium are closely related, but the relationship may vary in settings of abnormal albumin concentrations, pH extremes, and during blood transfusions. As an example, each 1 g/dL reduction in the serum albumin concentration will lower the total calcium concentration by approximately 0.8 mg/dL (0.2 mmol/L), without affecting the ionized calcium concentration. (See  <a class="medical medical_review" href="/d/html/837.html" rel="external">"Diagnostic approach to hypocalcemia", section on 'Confirm hypocalcemia'</a>.)</p><p>Although both measures are relatively constant over the lifespan, the upper limit of the normal range may be greater in infants, particularly during the first three months of life. In one study of healthy infants during the first year of life, serum ionized calcium concentrations were [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>1 month of age – Mean 5.6 mg/dL (1.4 mmol/L); observed range 5.2 to 6.1 mg/dL (1.29 to 1.52 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>3 months of age – Mean 5.5 mg/dL (1.38 mmol/L); observed range 5.2 to 6.0 mg/dL (1.30 to 1.49 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>12 months of age – Mean 5.3 mg/dL (1.33 mmol/L); observed range 5.0 to 5.6 mg/dL (1.24 to 1.39 mmol/L)</p><p></p><p>After 12 months of age, normal ranges typically used for clinical purposes are:</p><p class="bulletIndent1"><span class="glyph">●</span>Ionized calcium – 4.65 to 5.25 mg/dL (1.2 to 1.3 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Total calcium – 8.5 to 10.5 mg/dL (2.12 to 2.62 mmol/L)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">NORMAL CALCIUM HOMEOSTASIS</span><span class="headingEndMark"> — </span>Two major and interrelated calciotropic hormonal systems, parathyroid hormone (PTH) and vitamin D, are central to calcium homeostasis and function, as described below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PTH</strong> – PTH serves as the primary protection against acute hypocalcemia. PTH is released from the parathyroid chief cells. The calcium-sensing receptor (CaSR) resides on the plasma membrane of the chief cells and serves as a "calcistat," which continuously senses ambient ionized calcium concentration. Acute changes in ionized calcium levels are immediately detected by the CaSR, which effects a rapid increase or decrease in PTH secretion based on the direction of change in ionized calcium. This classic negative endocrine feedback loop allows for an increase in PTH as ionized calcium concentration decreases, engaging mechanisms to increase the ionized calcium level. As ionized calcium levels rise, there is suppression of PTH secretion to maintain the steady-state narrow range of ionized calcium levels.</p><p></p><p class="bulletIndent1">PTH acts to increase serum calcium by:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mobilizing calcium from the bone – Via stimulation of osteoclastic bone resorption and release of calcium from a rapidly exchangeable calcium pool</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stimulating 1-alpha-hydroxylase in the kidney – Thereby converting 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (the active form of vitamin D), which directly increases intestinal calcium absorption</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Directly increasing calcium reabsorption in the distal renal tubule</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D</strong> – 1,25-dihydroxyvitamin D, the active metabolite of vitamin D, promotes calcium and phosphorus absorption from the gastrointestinal tract. Lesser effects on calcium reabsorption from the renal tubules may also occur. Exposure to pharmacologic amounts of 1,25-dihydroxyvitamin D may also affect bone resorption, with net movement of calcium into the blood.</p><p></p><p>The hormone calcitonin plays a less critical role in calcium homeostasis. Calcitonin is synthesized in and released from the parafollicular cells of the thyroid gland when the circulating concentration of ionized calcium is increased. Calcitonin acts by decreasing bone resorption by osteoclasts.</p><p>A more detailed discussion of calcium homeostasis is found elsewhere. (See  <a class="medical medical_review" href="/d/html/2050.html" rel="external">"Parathyroid hormone secretion and action"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The primary determinant of symptoms and signs in patients with hypocalcemia is the circulating ionized calcium concentration. A low ionized calcium concentration results from either decreased entry of calcium into the circulation (gastrointestinal malabsorption, decreased bone reabsorption, eg, due to hypoparathyroidism or hypovitaminosis D) or increased loss of ionized calcium from the circulation (deposition in tissue, loss in urine, or increased binding of calcium in serum)  (<a class="graphic graphic_table graphicRef53781" href="/d/graphic/53781.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/833.html" rel="external">"Clinical manifestations of hypocalcemia"</a>.)</p><p>Acute hypocalcemia is generally caused by rapid movement of calcium from the circulation to other tissue compartments or by formation of complexes of the calcium ion with phosphate, other counterions, or protein binding. For example, phosphate administration may lower serum ionized calcium concentrations by promoting formation of calcium-phosphate complexes, and precipitation of mineral in soft tissue or bone matrix. Alkalosis decreases the concentration of serum ionized calcium by increasing the binding of ionized calcium to albumin. Ingestion of ammonium bifluoride (an ingredient of glass-etching creams) can form calcium complexes and thereby acutely lower circulating ionized calcium concentrations [<a href="#rid2">2</a>].</p><p>Chronic or subacute hypocalcemia mainly results from long-term dysfunction of the primary organs mediating calcium movement (intestine, bone, and kidney) or defects in the calcium homeostatic system. In some cases, the hypocalcemia is caused by primary disturbances of these organs such as short gut (resulting in inadequate calcium absorption) or osteopetrosis (resulting in failure to mobilize calcium from bone). In the absence of such a defect, disturbances in the hormonal control of calcium homeostasis, such as hypoparathyroidism or vitamin D deficiency, may cause chronic hypocalcemia. (See <a class="local">'Normal calcium homeostasis'</a> above.)</p><p class="headingAnchor" id="H4"><span class="h1">NEONATAL HYPOCALCEMIA</span><span class="headingEndMark"> — </span>Hypocalcemia is common in the newborn period and often transient, particularly in infants who are sick or have low birth weights. Persistent hypocalcemia may also present during the neonatal period and will be defined with time of follow-up such that therapy directed to the specific etiology can be provided. This disorder is discussed in more detail in a separate topic review. (See  <a class="medical medical_review" href="/d/html/5060.html" rel="external">"Neonatal hypocalcemia"</a>.)</p><p class="headingAnchor" id="H266913718"><span class="h2">Transient</span><span class="headingEndMark"> — </span>Transient neonatal hypocalcemia can be divided into early and late forms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early transient</strong> – Early transient neonatal hypocalcemia is defined as occurring within 72 hours of life. It is often caused by multiple factors that interrupt parathyroid hormone (PTH) secretion or action and coincide to exaggerate the postnatal physiologic nadir of serum calcium levels. Such factors include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal factors – These include maternal vitamin D deficiency, use of anticonvulsants, diabetes (either permanent or gestational), hyperparathyroidism, and toxemia of pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neonatal factors – These include prematurity, low birth weight, intrauterine growth retardation, and birth asphyxia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Concurrent illness – Other illnesses commonly seen in the neonate such as sepsis, respiratory distress syndrome, hypomagnesemia, hyperbilirubinemia including phototherapy, and renal failure can contribute to hypocalcemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exogenous or iatrogenic factors – The administration of excess phosphate, lipid infusions, citrated blood, and bicarbonate can cause a decrease in circulating ionized calcium concentrations. Inadequate calcium in parenteral nutrition solutions may also contribute to this problem.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late transient</strong> – Late transient neonatal hypocalcemia develops after 72 hours of life and has been attributed to the relatively large phosphate load occurring with cow's milk and cow's milk formulas.</p><p></p><p class="bulletIndent1">Encouraging breastfeeding or the use of a low-phosphate formula such as Similac PM 60/40 is useful. In our experience, these late-presenting cases are less likely to be transient compared with those presenting within the first 72 hours of life.</p><p></p><p class="headingAnchor" id="H266913724"><span class="h2">Persistent</span><span class="headingEndMark"> — </span>Cases of either early- or late-presenting hypocalcemia that progress or fail to resolve should be investigated. The investigations should identify the nature of calcium supply (parenteral and enteral, dietary, and supplement use) and whether or not PTH levels are appropriately elevated in response to the hypocalcemia. Causes of persistent hypocalcemia are discussed below.</p><p class="headingAnchor" id="H7"><span class="h1">HYPOCALCEMIA WITH LOW PTH (HYPOPARATHYROIDISM)</span><span class="headingEndMark"> — </span>Hypoparathyroidism can be classified by its pathogenesis  (<a class="graphic graphic_table graphicRef53781" href="/d/graphic/53781.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired synthesis or secretion of parathyroid hormone (PTH) due to lack or loss of parathyroid gland (tissue) or to a defect in the synthesis or release of PTH. This can be either a primary or acquired condition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Defects in the calcium-sensing receptor (CaSR) or related proteins.</p><p></p><p>A similar clinical picture can be caused by end-organ resistance to PTH (pseudohypoparathyroidism [PHP]), which is distinguished by high rather than low PTH. (See <a class="local">'End-organ resistance to PTH (pseudohypoparathyroidism)'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h2">Genetic mechanisms</span><span class="headingEndMark"> — </span>Several genetic defects have been identified in patients with hypoparathyroidism  (<a class="graphic graphic_table graphicRef142074" href="/d/graphic/142074.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DiGeorge syndrome and related disorders</strong> – Some patients with DiGeorge syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F188400&amp;token=87jLzclRwWxNoI%2BQq5Gg73wsO5Lm8wLESZko9AnvggSCxU6CWyhAB3UgJTvkzzyn&amp;TOPIC_ID=5846" target="_blank">MIM #188400</a>) have hypoparathyroidism, which is caused by parathyroid aplasia or hypoplasia. The hypoparathyroidism may present with hypocalcemia during the neonatal period or it may occur later in life, in the setting of increased demands for PTH with diminished parathyroid reserve.</p><p></p><p class="bulletIndent1">DiGeorge syndrome is a result of abnormal development of the third and fourth branchial pouches. Other features include thymic aplasia or hypoplasia, cardiac defect affecting the outflow tract, developmental delay, and a characteristic facial appearance (prominent nose, squared nasal root). Most cases are sporadic, but familial cases with autosomal dominant inheritance have been reported. Most patients have deletion of the region of chromosome 22q11.2. (See  <a class="medical medical_review" href="/d/html/3905.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/83396.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis", section on 'Hypocalcemia'</a>.)</p><p></p><p class="bulletIndent1">A deletion on chromosome 10p can result in DiGeorge syndrome type 2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601362&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyo7chnObwlyrriLAT2I%2F1Yo&amp;TOPIC_ID=5846" target="_blank">MIM 601362</a>). Candidate responsible genes in the region include <em>GATA3</em> (GATA-binding protein 3; see HDR syndrome below) and <em>NEBL</em> (nebulette), encoding an actin-binding protein associated with cardiac development; the mechanism of hypoparathyroidism is unknown [<a href="#rid3">3,4</a>]. The CHARGE syndrome (coloboma, heart anomalies, choanal atresia, retardation of growth and development, genital and ear/hearing anomalies) due to heterozygous mutations in <em>CHD7</em> may also present with hypoparathyroidism. The protein encoded is a DNA-binding protein involved in chromatin remodeling [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/3905.html" rel="external">"DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Defects on other chromosomes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal recessive</strong> – Several families with autosomal recessive hypoparathyroidism have been identified [<a href="#rid6">6-9</a>]. Two had a missense mutation in the signal peptide [<a href="#rid6">6,8</a>]; these mutations also affect the processing of pre-pro-parathyroid hormone (preproPTH). In one kindred with autosomal recessive hypoparathyroidism, the underlying defect was homozygous loss of function of the <em>GCM2</em> gene (glial cells missing) [<a href="#rid10">10</a>]. In mice, the homologous <em>Gcm2</em> gene, which is expressed exclusively in the parathyroid gland, encodes a transcription factor that is essential for parathyroid gland development [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HDR syndrome</strong> – An autosomal dominant form of hypoparathyroidism associated with sensorineural deafness and renal dysplasia (HDR syndrome, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F146255&amp;token=87jLzclRwWxNoI%2BQq5Gg78R5JXTy2Z3%2FiTH2yesJLEG5IiEbjK3yuyBcqAHRnUUC&amp;TOPIC_ID=5846" target="_blank">MIM #146255</a>) has been reported [<a href="#rid11">11,12</a>]. Mutations in <em>GATA3</em>, a gene localized to the chromosome region 10p14-15, have been detected in families affected by the syndrome [<a href="#rid13">13,14</a>]. <em>GATA3</em> is a transcription factor that is involved in the embryonic development of the parathyroid glands, kidneys, inner ears, thymus, and central nervous findings. Similar clinical findings were reported in families with an apparent autosomal recessive mode of inheritance [<a href="#rid7">7,15</a>].</p><p></p><p class="bulletIndent1">Barakat described two sets of brothers with hypoparathyroidism, sensorineural deafness, and steroid-resistant nephrotic syndrome [<a href="#rid16">16</a>]. This was termed Barakat syndrome, but it shares many of the same clinical manifestations as HDR syndrome. These disorders are thought to be the same entity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sanjad-Sakati and Kenny-Caffey syndromes</strong> – Sanjad-Sakati syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F241410&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2BFEmQ667lDwUMKLcOIkFJ%2BP%2BujPkd5OLcql3h6i2IDl&amp;TOPIC_ID=5846" target="_blank">MIM #241410</a>) and the autosomal recessive form of Kenny-Caffey syndrome (Kenny-Caffey type 1, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F244460&amp;token=87jLzclRwWxNoI%2BQq5Gg731cUFzgKqjZDaZYHW8Etr4TNttwRM33G%2FBIk8mMcSLF&amp;TOPIC_ID=5846" target="_blank">MIM #244460</a>) share the same clinical features including congenital hypoparathyroidism, intellectual disability, facial dysmorphism, and severe growth failure [<a href="#rid17">17,18</a>]. Patients with Kenny-Caffey type 1 also have osteosclerosis and immunodeficiency [<a href="#rid19">19</a>]. Sanjad-Sakati syndrome has been reported almost exclusively in Arab families. Both disorders map to 1q42-q43 [<a href="#rid20">20</a>] and are caused by mutations in the <em>TBCE</em> gene (tubulin-specific chaperone E), which encodes a protein involved in tubulin folding [<a href="#rid21">21</a>]. This finding suggests the two disorders are likely allelic or constitute different reports of the same condition. Yet another similar phenotype, Kenny-Caffey syndrome type 2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F127000&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1Su7IeLC%2FwBDkLrTA4SryDy&amp;TOPIC_ID=5846" target="_blank">MIM #127000</a>), is an autosomal dominant disorder due to heterozygous mutations in the <em>FAM111A</em> gene (family with sequence similarity 111, member A) and differs from the type 1 syndrome in its absence of intellectual disability [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutations in the CaSR and related proteins</strong> – Autosomal dominant hypocalcemia (ADH) is most frequently caused by an activating mutation of the CaSR; this type is known as ADH 1 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601198&amp;token=87jLzclRwWxNoI%2BQq5Gg76hrxa%2B7y9DsZeNoJPhC6tm2YDVJr9bzOADQPsta7qaR&amp;TOPIC_ID=5846" target="_blank">MIM #601198</a>). The activating mutation causes hypocalcemia by shifting the set point of CaSR such that PTH is not released at serum calcium concentrations that normally trigger PTH release. Renal calcium reabsorption in these patients is also lower than anticipated because of the absence of PTH secretion. ADH 2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F615361&amp;token=87jLzclRwWxNoI%2BQq5Gg7w4rpd%2FxejXu7t4awHq9MfeWse9dgmYlEECLQB8fFqco&amp;TOPIC_ID=5846" target="_blank">MIM #615361</a>) is caused by activating mutations in the <em>GNA11</em> gene (guanine nucleotide-binding protein, alpha-11), a GTPase which mediates downstream CaSR signaling. Autosomal dominant inheritance also has been described for the inhibitor mutations of PTH and <em>GCM2</em> described above.</p><p></p><p class="bulletIndent1">Although patients with ADH can present in the neonatal period, it is not uncommon for subjects to be asymptomatic with mild to moderate hypocalcemia. However, during periods of stress such as a febrile illness, patients can become symptomatic with seizures and neuromuscular irritability (tetany). It is the authors' experience that some of these patients escape detection by being mislabeled as children with febrile seizures; hence the importance of screening serum calcium in any child presenting with seizures.</p><p></p><p class="bulletIndent1">ADH is uncommon in the general population, but it is often confused with the diagnosis of isolated primary hypoparathyroidism. Patients with ADH caused by the CaSR mutation have hypocalcemia with an inappropriately normal PTH concentration and relative hypercalciuria. Urinary calcium excretion does not appear to be affected in patients with ADH due to <em>GNA11</em> mutations.</p><p></p><p class="bulletIndent1">Details of the genetic defect, diagnosis, and treatment of ADH are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/838.html" rel="external">"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked</strong> – X-linked recessive hypoparathyroidism caused by a deletion-insertion rearrangement involving chromosomes Xq27.1 and 2p25.3 has been described in two related kindreds [<a href="#rid23">23,24</a>]. Affected male infants develop hypocalcemia with seizures because of an isolated defect in the development of the parathyroid gland.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PTH gene mutation</strong> – An autosomal dominant mutation in the signal peptide sequence of preproPTH has been described, which impairs the normal processing of preproPTH to PTH [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitochondrial disorders</strong> have been associated with hypoparathyroidism [<a href="#rid26">26,27</a>]. These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kearns-Sayre syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F530000&amp;token=87jLzclRwWxNoI%2BQq5Gg73PUDOXR9a51bb21LFj9QviHSq5qgJlvKHciI%2B6iLEG5&amp;TOPIC_ID=5846" target="_blank">MIM #530000</a>), characterized by ophthalmoplegia, pigmentary degeneration of the retina, and cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/6271.html" rel="external">"Myopathies affecting the extraocular muscles in children", section on 'Kearns-Sayre syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F540000&amp;token=87jLzclRwWxNoI%2BQq5Gg78rdzGng57%2BUERMWba9lkxl3s4Jqy2oG45DVDUnaQO99&amp;TOPIC_ID=5846" target="_blank">MIM #540000</a>), characterized by mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. (See  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'MELAS'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mitochondrial trifunctional protein deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F609015&amp;token=87jLzclRwWxNoI%2BQq5Gg7995CXLOi56DQqf2q8zl7lRByD9QFxvSn55ZoYdH7lds&amp;TOPIC_ID=5846" target="_blank">MIM #609015</a>) is a fatty acid oxidation disorder that can present either as a severe condition with neonatal cardiomyopathy and sudden death, infantile onset of a hepatic Reye-like syndrome, or late adolescent onset of skeletal myopathy. Hypocalcemia or pigmentary retinopathy were reported in some cases. In some cases, mothers of an affected fetus have acute liver degeneration during pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other mitochondrial disorders have also been associated with hypoparathyroidism, including medium-chain acyl-CoA dehydrogenase deficiency and Pearson syndrome, by unknown mechanisms [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/115918.html" rel="external">"Specific fatty acid oxidation disorders", section on 'Medium-chain acyl-CoA dehydrogenase deficiency'</a> and  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'Pearson syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Autoimmune mechanisms</span><span class="headingEndMark"> — </span>Hypoparathyroidism is part of the autoimmune polyglandular syndrome type 1 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F240300&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FfWzCTGwFXhORtgmdRwWxSPRob3gbdKo6N1THWxtH2a&amp;TOPIC_ID=5846" target="_blank">MIM #240300</a>), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome. In these patients, immunologic destruction of the parathyroid gland occurs in association with destruction of other endocrine glands. APECED results from mutations in the <em>AIRE</em> gene (autoimmune regulator), which is expressed in the thymus, lymph nodes, pancreas, adrenal cortex, and fetal liver. Antibodies to the CaSR also have been reported to cause hypoparathyroidism [<a href="#rid29">29</a>].</p><p>The three principal findings include hypoparathyroidism, primary adrenal insufficiency, and chronic mucocutaneous candidiasis. Hypoparathyroidism or candidiasis are typically the first manifestations to appear during childhood or adolescence. Because of these associations, a child with hypoparathyroidism should be examined frequently for other endocrinopathies. (See  <a class="medical medical_review" href="/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Autoimmune regulator deficiency'</a>.)</p><p>This disorder is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Type 1 (monogenic)'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Other acquired mechanisms</span><span class="headingEndMark"> — </span>Hypoparathyroidism can be acquired in the following clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Parathyroidectomy to remove a parathyroid adenoma or hyperplastic glands (eg, in patients with end-stage kidney failure and hyperparathyroidism). The presurgical hypercalcemia suppresses PTH from the remaining glands, resulting in transient hypoparathyroidism and hypocalcemia immediately after surgery. In addition, some patients may develop the hungry bone syndrome, which increases the severity of hypocalcemia postoperatively. (See <a class="local">'Hungry bone syndrome'</a> below and  <a class="medical medical_review" href="/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During thyroid surgery, as a result of manipulation of the blood supply to or removal of one or more parathyroid glands. In most cases, the hypoparathyroidism and hypocalcemia are transient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iron deposition in the parathyroid gland in patients requiring chronic transfusions (eg, beta thalassemia major) [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Copper deposition in patients with Wilson disease [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/3626.html" rel="external">"Wilson disease: Epidemiology and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-negative sepsis, toxic shock syndrome, and HIV infection also may be complicated by hypocalcemia through mechanisms that include impaired PTH secretion and resistance. (See <a class="local">'Sepsis or acute severe illness'</a> below and  <a class="medical medical_review" href="/d/html/3738.html" rel="external">"Bone and calcium disorders in patients with HIV", section on 'Alterations in bone and calcium metabolism'</a>.)</p><p></p><p class="headingAnchor" id="H1305682"><span class="h1">HYPOCALCEMIA WITH HIGH PTH</span><span class="headingEndMark"> — </span>Hypocalcemia with elevated serum concentrations of parathyroid hormone (PTH) is most often caused by vitamin D-related pathology, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Insufficient dietary intake, intestinal absorption or skin production of vitamin D (hypovitaminosis D)</p><p class="bulletIndent1"><span class="glyph">●</span>Defects in vitamin D metabolism (physiologic or genetic)</p><p class="bulletIndent1"><span class="glyph">●</span>End-organ resistance to vitamin D (hereditary resistance to vitamin D [HRVD])</p><p></p><p>Vitamin D-independent causes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Deficient dietary intake or intestinal absorption of calcium</p><p class="bulletIndent1"><span class="glyph">●</span>End-organ resistance to PTH (pseudohypoparathyroidism [PHP])</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of calcium from the circulation, which may occur in "hungry bone syndrome," osteopetrosis, hyperphosphatemia, and pancreatitis (see <a class="local">'Miscellaneous'</a> below)</p><p></p><p>These disorders are outlined in the table  (<a class="graphic graphic_table graphicRef53781" href="/d/graphic/53781.html" rel="external">table 1</a>) and described below.</p><p class="headingAnchor" id="H2661187952"><span class="h2">Deficient calcium intake or intestinal absorption</span><span class="headingEndMark"> — </span>Very low dietary intake or malabsorption of calcium can cause nutritional rickets. Occasionally, rickets occurs even in the setting of normal vitamin D [<a href="#rid32">32</a>]. More often, combined dietary deficiencies of both vitamin D and calcium contribute to nutritional rickets. Dietary deficiency of calcium may promote increased turnover of vitamin D stores [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children", section on 'Calcium deficiency'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Deficient vitamin D intake, intestinal absorption and/or dermal synthesis</span><span class="headingEndMark"> — </span>Clinical deficiency of vitamin D is identified by decreased concentrations of the most abundant circulating vitamin D metabolite, 25-hydroxyvitamin D. This disorder is characterized by elevated PTH and normal or low serum inorganic phosphorus levels and can cause the clinical syndrome of calcipenic rickets  (<a class="graphic graphic_algorithm graphicRef79880" href="/d/graphic/79880.html" rel="external">algorithm 1</a>). Plasma calcium is often low but may be normal because of the actions of compensatory PTH secretion. The circulating 1,25-dihydroxyvitamin D level is not a useful discriminant for this condition and may be low, normal, or elevated. Thus, we do not recommend its measurement as a primary investigation when vitamin D deficiency is the primary consideration for the diagnosis.</p><p>Vitamin D deficiency is usually the result of decreased intake, but limited sunlight (exposure to ultraviolet radiation) may substantially contribute. In the United States, most vitamin D is derived from foods that have a high content of the vitamin (fatty fishes) or are fortified with the vitamin (milk and related products and cereals). The remainder is synthesized in the skin from 7-dehydrocholesterol under the influence of ultraviolet light. Hence, vitamin D deficiency can occur in children whose dietary intake is low and/or who live without sun exposure. These children frequently have a low calcium intake as well, which contributes to the nutritional rickets. (See  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children", section on 'Nutritional rickets'</a>.)</p><p>In infants who are exclusively breastfed, vitamin D deficiency can occur if vitamin D supplementation is not provided, especially in dark-skinned infants during the winter months [<a href="#rid34">34</a>]. It is recommended that all breastfed infants be provided daily with 400 international units of vitamin D for this reason. (See  <a class="medical medical_review" href="/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents", section on 'Pathogenesis and risk factors'</a>.)</p><p>Decreased intestinal absorption of vitamin D may also contribute to reduced 25-hydroxyvitamin D stores. This may be caused by gastrectomy, celiac disease, malabsorption, extensive bowel surgery, inflammatory bowel disease, or pancreatic insufficiency as seen in cystic fibrosis. (See  <a class="medical medical_review" href="/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents", section on 'Malabsorption and other medical conditions'</a>.)</p><p class="headingAnchor" id="H262457169"><span class="h2">Defects in vitamin D metabolism</span><span class="headingEndMark"> — </span>Vitamin D from the diet or dermal synthesis is biologically inactive and requires enzymatic conversion in the liver and kidney to the active metabolite, 1,25-dihydroxyvitamin D  (<a class="graphic graphic_figure graphicRef65360" href="/d/graphic/65360.html" rel="external">figure 1</a>). Physiologic or genetic disturbances in this process may lead to hypocalcemia, with compensatory PTH secretion. (See  <a class="medical medical_review" href="/d/html/2033.html" rel="external">"Overview of vitamin D"</a>.)</p><p class="headingAnchor" id="H3553256705"><span class="h3">Hepatic dysfunction</span><span class="headingEndMark"> — </span>In the liver, vitamin D undergoes 25-hydroxylation to produce 25-hydroxyvitamin D. This conversion can be impaired in patients with severe liver disease. Drugs such as anticonvulsants (eg, <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a>, <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a>, <a class="drug drug_pediatric" data-topicid="13113" href="/d/drug information/13113.html" rel="external">carbamazepine</a>, <a class="drug drug_pediatric" data-topicid="13393" href="/d/drug information/13393.html" rel="external">isoniazid</a>, <a class="drug drug_pediatric" data-topicid="12831" href="/d/drug information/12831.html" rel="external">theophylline</a>, and <a class="drug drug_pediatric" data-topicid="12767" href="/d/drug information/12767.html" rel="external">rifampin</a>) can also reduce available 25-hydroxyvitamin D. Although they increase the activity of P-450 enzymes that increase 25-hydroxylation, they also increase the catabolism of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D to inactive metabolites.</p><p class="headingAnchor" id="H1061209081"><span class="h3">Renal dysfunction</span><span class="headingEndMark"> — </span>The final and rate-limiting step in vitamin D metabolism is the 1-hydroxylation of 25-hydroxyvitamin D in the kidney to produce 1,25-dihydroxyvitamin D, the most biologically active metabolite of vitamin D. This reaction is stimulated by PTH and hypophosphatemia but inhibited by calcium, phosphate, or fibroblast growth factor 23 (FGF23). In patients with renal failure, 1,25-dihydroxyvitamin D production is low because of the reduced expression of 1-hydroxylase, which occurs with rising circulating levels of FGF23, evident during progressive stages of chronic kidney disease. Thus, vitamin D plays a role in the development of the bone disease seen in chronic kidney disease. (See  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p class="headingAnchor" id="H1591656723"><span class="h3">Genetic disorders</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>25-hydroxylase deficiency </strong>– 25-hydroxylase deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600081&amp;token=87jLzclRwWxNoI%2BQq5Gg790GCJ0HqNejgXFDB2kMViEE2pIjTL8U%2FUqfE8yB1mOZ&amp;TOPIC_ID=5846" target="_blank">MIM #600081</a>) results in defective hepatic 25-hydroxylation vitamin D, and appears to be rare [<a href="#rid35">35</a>]. It is caused by mutations in <em>CYP2R1</em>, the gene that encodes synthesis of 25-hydroxylase, the major enzyme that catalyzes the production of 25-hydroxyvitamin D in the liver [<a href="#rid35">35</a>]. Biochemically, the disorder is difficult to distinguish from vitamin D deficiency as the serum 25-hydroxyvitamin D is low. It is often identified after poor clinical responses to documented administration of therapeutic doses of vitamin D. (See  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children", section on '25-hydroxylase deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>1-alpha-hydroxylase deficiency</strong> – 1-alpha-hydroxylase deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F264700&amp;token=87jLzclRwWxNoI%2BQq5Gg704lyzSCGyCZfNK54Celwnu8Ez0t6zWcaecAkQb2Js7T&amp;TOPIC_ID=5846" target="_blank">MIM #264700</a>) is distinguished by defective renal 1-hydroxylation of 25-hydroxyvitamin D. It is caused by biallelic loss-of-function mutations in <em>CYP27B1</em>, which encodes the cytochrome P450 component of the 1-alpha-hydroxylase enzyme complex that catalyzes the conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D [<a href="#rid36">36-38</a>]. The defective enzyme has impaired binding to either the substrate, 25-hydroxyvitamin D, or a requisite cofactor.</p><p></p><p class="bulletIndent1">Clinical features include hypocalcemia, hypophosphatemia, elevated alkaline phosphatase levels, and rickets, with an autosomal recessive pattern of inheritance [<a href="#rid39">39</a>]. Serum concentrations of 25-hydroxyvitamin D levels are not low, whereas the circulating 1,25-dihydroxyvitamin D concentration may be decreased. This disorder can be treated with small doses of oral 1,25-dihydroxyvitamin D (<a class="drug drug_pediatric" data-topicid="13107" href="/d/drug information/13107.html" rel="external">calcitriol</a>). Because it also responds to pharmacologic doses of vitamin D (<a class="drug drug_pediatric" data-topicid="13086" href="/d/drug information/13086.html" rel="external">cholecalciferol</a> or <a class="drug drug_pediatric" data-topicid="13274" href="/d/drug information/13274.html" rel="external">ergocalciferol</a>), 1-alpha-hydroxylase deficiency was previously known as vitamin D-dependent rickets type 1 or pseudovitamin D-deficient rickets. (See  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children", section on '1-alpha-hydroxylase deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased catabolism of vitamin D</strong> – Gain-of-function mutations in <em>CYP3A4 </em>(<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F619073&amp;token=87jLzclRwWxNoI%2BQq5Gg7yxNQfZ25EPtB23fBREA9RAVJXfop9r%2BWpRndE2B0iVo&amp;TOPIC_ID=5846" target="_blank">MIM #619073</a>), the gene encoding the vitamin D catabolic enzyme, cause increase degradation of both 25-hydroxyvitamin D and the active 1,25-dihydroxyvitamin D metabolite [<a href="#rid40">40</a>]. Affected patients have low circulating levels of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, indicating that genetic dysregulation of vitamin D catabolism, which can lead to a rachitic phenotype.</p><p></p><p class="headingAnchor" id="H142171432"><span class="h2">Defect in vitamin D action</span></p><p class="headingAnchor" id="H22"><span class="h3">Hereditary resistance to vitamin D</span><span class="headingEndMark"> — </span>HRVD (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F277440&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2B4WWa4cHSTVg9AumYDSGOyHR0lc2wu0d082Un75MqPx&amp;TOPIC_ID=5846" target="_blank">MIM #277440</a>), previously known as vitamin D-dependent rickets type 2 [<a href="#rid41">41</a>], is caused by end-organ resistance to 1,25-dihydroxyvitamin D, most often because of biallelic loss-of-function mutations in the gene encoding the vitamin D receptor, located in chromosome region 12q13-14 [<a href="#rid42">42-44</a>]. Mutations in the <em>HNRNPC</em> gene (heterogeneous nuclear ribonucleoprotein C), which encodes a coactivator of the vitamin D receptor, can also cause this syndrome [<a href="#rid45">45</a>].</p><p>The clinical findings of HRVD are similar to those observed in 1-alpha-hydroxylase deficiency (hypocalcemia, hypophosphatemia, and high PTH and alkaline phosphatase concentrations), except that serum 1,25-dihyroxyvitamin D concentrations are high rather than low. In addition to rickets, many of the patients have alopecia. Therapy with pharmacological doses of 1,25-dihyroxyvitamin D or 25-hydroxyvitamin D are ineffective in most but not all cases [<a href="#rid46">46</a>]. The rickets can be improved with long-term, high-dose intravenous calcium therapy [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children", section on 'Hereditary resistance to vitamin D'</a>.)</p><p class="headingAnchor" id="H1308550"><span class="h2">End-organ resistance to PTH (pseudohypoparathyroidism)</span><span class="headingEndMark"> — </span>Pseudohypoparathyroidism (PHP) refers to a group of heterogeneous disorders defined by targeted organ (kidney and bone) unresponsiveness to PTH [<a href="#rid49">49-51</a>]. PTH resistance is characterized by:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypocalcemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperphosphatemia</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated PTH concentrations</p><p></p><p>The types and mechanisms of PHP are outlined below. Detailed reviews of the topic are available [<a href="#rid52">52,53</a>]. Treatment of PHP is discussed in a separate topic review. (See  <a class="medical medical_review" href="/d/html/826.html" rel="external">"Treatment of hypocalcemia", section on 'Pseudohypoparathyroidism'</a>.)</p><p class="headingAnchor" id="H1308646"><span class="h3">Type 1 PHP</span><span class="headingEndMark"> — </span>In patients with PHP type 1, there is a diminished urinary cyclic adenosine monophosphate (cAMP) response to exogenous PTH administration. There are several subtypes of PHP type 1 caused by mutations of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F139320&amp;token=tEpDslnpc0F0kICl%2Fz7sFakATHRTAlgxtyC0kXeRiukjv065MfTOGzZSiidGr6Mp&amp;TOPIC_ID=5846" target="_blank"><i>GNAS1</i></a> gene, which encodes the alpha subunit of a GTP-binding protein (Gs, or G protein), which couples to the PTH receptor in a cyclical manner [<a href="#rid54">54</a>]. These gene mutations result in the G protein's inability to activate adenyl cyclase upon the binding of PTH to its receptor [<a href="#rid55">55-57</a>]. Activation of adenyl cyclase is required for signal transduction that produces the end-organ response to PTH. Failure of signal transduction results in the unresponsiveness of the end-organ.</p><p><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F139320&amp;token=tEpDslnpc0F0kICl%2Fz7sFakATHRTAlgxtyC0kXeRiukjv065MfTOGzZSiidGr6Mp&amp;TOPIC_ID=5846" target="_blank"><i>GNAS1</i></a> is imprinted in humans so that expression of the allele for a specific tissue is dependent on whether the allele is maternally or paternally inherited; therefore, the disease manifestations also differ depending on the parent of origin [<a href="#rid58">58</a>]. As an example, renal expression of <em>GNAS1</em> appears to be determined only by the maternal allele, so that a defect only in the maternal allele of <em>GNAS1</em> will result in unresponsiveness of the renal tubule to PTH binding. This difference in tissue expression, based upon parental transmission and whether the underlying mutation leads to a <em>GNAS1</em> structural or expression defect, appears to contribute to the differences in the various forms of PHP.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1a</strong> – PHP type 1a (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F103580&amp;token=87jLzclRwWxNoI%2BQq5Gg75XvA7nx1OGAwb3Y3pT8tWl%2FfKcr85LUv1bNa36P67J%2B&amp;TOPIC_ID=5846" target="_blank">MIM #103580</a>) is an autosomal dominant disease with a loss-of-function mutation of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F139320&amp;token=tEpDslnpc0F0kICl%2Fz7sFakATHRTAlgxtyC0kXeRiukjv065MfTOGzZSiidGr6Mp&amp;TOPIC_ID=5846" target="_blank"><i>GNAS1</i></a>, leading to an inability to activate adenyl cyclase when PTH binds to its receptor [<a href="#rid59">59</a>]. Maternal transmission of the mutation is required for expression of PHP type 1a [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1">Patients with PHP type 1a have a constellation of findings known as Albright hereditary osteodystrophy (AHO), which includes round facies, short stature, short metacarpal bones (especially III-V), obesity, subcutaneous calcifications, and developmental delay [<a href="#rid49">49,61,62</a>]. Sleep apnea and metabolic syndrome are often encountered. Craniosynostosis may occur, as well as gonadal dysfunction and infertility. In addition, the PTH resistance of the renal tubule leads to hyperphosphatemia, hypocalcemia, and secondary hyperparathyroidism and hyperparathyroid bone disease (osteitis fibrosa).</p><p></p><p class="bulletIndent1">In humans, <em>GNAS1</em> also is predominantly expressed from the maternal allele in the thyroid, gonads, and pituitary glands. As a result, patients with PHP type 1a show resistance to various other G-protein coupled hormones including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and gonadotropin-releasing hormone (GnRH), as well as blunted response to beta-adrenergic agonists [<a href="#rid63">63,64</a>]. (See  <a class="medical medical_review" href="/d/html/7435.html" rel="external">"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)", section on 'Gs alpha subunit gene mutations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pseudo-pseudohypoparathyroidism</strong> – By contrast to patients with maternally transmitted mutations that result in loss of <em>GNAS1</em> function, those with paternally transmitted mutations have the phenotype of AHO but with normal serum calcium concentrations and without renal tubular resistance to PTH; this pattern is termed "pseudo-pseudohypoparathyroidism" [<a href="#rid65">65,66</a>]. In these patients, the paternal transmission of a mutated <em>GNAS1</em> gene results in AHO, but the normal maternal allele results in the maintenance of renal responsiveness to PTH [<a href="#rid67">67,68</a>]. As a result, these patients have normal calcium homeostasis with <strong>normal</strong> concentrations of calcium, phosphate, and PTH.</p><p></p><p>Paternally inherited inactivating <em>GNAS1</em> mutations also can cause progressive osseous heteroplasia, a related autosomal dominant disorder characterized by extensive dermal ossification during childhood [<a href="#rid69">69</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1b</strong> – Patients with the PHP type 1b disease (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F603233&amp;token=87jLzclRwWxNoI%2BQq5Gg79CR9yooDyFs3sDlt0dgyrz55CXo5GjkQF8h0Lkk5EcS&amp;TOPIC_ID=5846" target="_blank">MIM #603233</a>) have hypocalcemia but do not have the phenotypic abnormalities of AHO. PTH resistance appears to be confined to the kidney in this disorder, leading to only hypocalcemia, hyperphosphatemia, and secondary hyperparathyroidism [<a href="#rid70">70</a>]. This rare autosomal dominant disorder appears to be caused by methylation defects or mutations that affect the regulatory elements of <em>GNAS1</em>, such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603666&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyph%2BUe6pIGFTQ9uhuzDkS4z&amp;TOPIC_ID=5846" target="_blank"><i>STX16</i></a>, rather than mutations in <em>GNAS1</em> itself [<a href="#rid71">71-73</a>]. Type 1b may be maternally transmitted as well as sporadically occurring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type 1c</strong> – PHP type 1c (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F612462&amp;token=87jLzclRwWxNoI%2BQq5Gg79SqAG5fXFPpFrtymfx3XfxqrU6fTe56ZAC3i%2BrUvdcW&amp;TOPIC_ID=5846" target="_blank">MIM #612462</a>) refers to a subgroup of cases in which coupling of the G protein to the PTH receptor is aberrant. The ability to stimulate adenyl cyclase remains intact but is no longer coupled to the binding of PTH and its receptor [<a href="#rid74">74</a>]. Patients with PHP type 1c are usually phenotypically similar to those with PHP type 1a.</p><p></p><p class="headingAnchor" id="H1309113"><span class="h3">Type 2 PHP and other forms of PTH resistance</span><span class="headingEndMark"> — </span>Patients with PHP type 2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F203330&amp;token=87jLzclRwWxNoI%2BQq5Gg72FeeUQCtJNhq0X26vMBtL2vPQnMxfYl8r28f%2FSMYna1&amp;TOPIC_ID=5846" target="_blank">MIM 203330</a>) do not have the features of AHO. They have normal or even elevated urinary cAMP concentrations in response to exogenous PTH administration but without a concomitant increase in phosphate excretion [<a href="#rid75">75,76</a>]. One genetic mechanism by which this has been documented to occur is with mutations in the <em>PRKAR1A</em> gene (protein kinase, cAMP-dependent, regulatory, type 1, alpha), which encodes the catalytic subunit of adenylate cyclase and incorporates a phenotype of multiple hormone resistance with acrodysostosis [<a href="#rid77">77</a>].</p><p>In our experience and that of others, some patients with recently treated vitamin D deficiency have a biochemical profile that resembles that of type 2 PHP [<a href="#rid78">78</a>]. Therefore, it is important to clarify the vitamin D status of such patients before confirming a diagnosis of type 2 PHP.</p><p>Of note, other acrodysostosis-associated mutations may also be associated with PTH resistance, including heterozygous mutations in the <em>PDE4D</em> gene (cAMP-specific 3′,5′-cyclic phosphodiesterase 4D) [<a href="#rid79">79</a>]<em> </em>and the <em>PDE3A</em> gene (phosphodiesterase 3A) [<a href="#rid80">80</a>]<em>.</em> Documentation of overt hypocalcemia in the setting of mutations in the <em>PTHR1</em> gene (PTH/PTHrP receptor) is lacking, although a spectrum of severity ranging from delayed tooth eruption to Blomstrand syndrome is described in this form of PTH resistance [<a href="#rid81">81,82</a>]. This panoply of defects has led to the consideration of a revised nomenclature for the PTH resistance syndromes [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H1307838"><span class="h1">MISCELLANEOUS</span></p><p class="headingAnchor" id="H1307844"><span class="h2">Hungry bone syndrome</span><span class="headingEndMark"> — </span>Hungry bone syndrome refers to a phase of avid bone mineralization, with hypocalcemia due to rapid movement of calcium from the circulation into the skeletal compartment; this tends to occur during the early phases of recovery from a severe mineralization defect or after a prolonged period of calcium resorption from bone. A parallel increase in bone uptake of magnesium leading to hypomagnesemia may increase the severity of hypocalcemia. The hungry bone syndrome may be triggered by vitamin D therapy in the setting of severe rickets, parathyroidectomy, or rarely by thyroidectomy. (See  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/2070.html" rel="external">"Hungry bone syndrome following parathyroidectomy in patients with end-stage kidney disease"</a>.)</p><p>Patients with type 1 Gaucher disease often develop transient hypocalcemia after initiation of enzyme replacement therapy, likely due to hungry bone syndrome [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/2934.html" rel="external">"Gaucher disease: Treatment", section on 'Enzyme replacement therapy'</a>.)</p><p class="headingAnchor" id="H262457159"><span class="h2">Osteopetrosis</span><span class="headingEndMark"> — </span>This disorder may result in significant loss of osteoclast function and decrease in bone resorption such that calcium mobilization from the skeleton is sufficiently impaired as to result in hypocalcemia.</p><p class="headingAnchor" id="H1307993"><span class="h2">Sepsis or acute severe illness</span><span class="headingEndMark"> — </span>Hypocalcemia may be triggered by Gram-negative sepsis, toxic shock syndrome, or severe burns. The mechanism is unknown but may be related to macrophage-generated cytokines, which can affect parathyroid hormone (PTH) and vitamin D secretion and action. (See  <a class="medical medical_review" href="/d/html/840.html" rel="external">"Etiology of hypocalcemia in adults", section on 'Sepsis or severe illness'</a>.)</p><p class="headingAnchor" id="H266913778"><span class="h2">Hyperphosphatemia</span><span class="headingEndMark"> — </span>Endogenous or exogenous sources of phosphate can cause hyperphosphatemia if they exceed the renal capacity for phosphate excretion, such as when small infants have received a phosphate-containing enema. The ensuing hyperphosphatemia may result in calcium-phosphate precipitation in the tissues leading to symptomatic hypocalcemia.</p><p>Acute hyperphosphatemia is seen in the setting of massive tissue breakdown (eg, tumor lysis and rhabdomyolysis) or with excessive phosphate intake. Use of phosphate-containing enemas may cause hyperphosphatemia. This is especially a problem in children with poor intestinal motility, such as those with chronic constipation or neuromuscular dysfunction including cerebral palsy or neurodegenerative disorders, and if multiple phosphate-containing enemas are given to small children [<a href="#rid85">85,86</a>].</p><p class="headingAnchor" id="H266913822"><span class="h2">Intravenous products with citrate or lactate</span><span class="headingEndMark"> — </span>Administration of large volumes of intravenous products that contain citrate (eg, blood products) or lactate may decrease the serum ionized calcium concentration through increased binding of calcium into calcium-citrate or calcium-lactate complexes.</p><p class="headingAnchor" id="H266913828"><span class="h2">Pancreatitis</span><span class="headingEndMark"> — </span>Hypocalcemia may occur in patients with acute pancreatitis. It is primarily caused by precipitation of calcium soaps in the abdominal cavity; glucagon-stimulated calcitonin release and decreased PTH secretion also may play a role.</p><p class="headingAnchor" id="H1307906"><span class="h2">Drugs and toxic ingestions</span><span class="headingEndMark"> — </span>Drugs that may cause hypocalcemia include bisphosphonates, <a class="drug drug_pediatric" data-topicid="110538" href="/d/drug information/110538.html" rel="external">denosumab</a>, calcimimetics (<a class="drug drug_pediatric" data-topicid="122817" href="/d/drug information/122817.html" rel="external">cinacalcet</a>), the antiviral agent <a class="drug drug_pediatric" data-topicid="13325" href="/d/drug information/13325.html" rel="external">foscarnet</a>, and some chemotherapeutic drugs. Rarely, excess intake of fluoride can cause hypocalcemia; this effect is presumably mediated by inhibition of bone resorption [<a href="#rid87">87</a>]. Other substances associated with consequent hypocalcemia following ingestion have been reported, including ammonium bifluoride. We and others have witnessed transient infantile hypocalcemia in the context of excessive maternal calcium ingestion [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/d/html/840.html" rel="external">"Etiology of hypocalcemia in adults", section on 'Drugs'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Hypomagnesemia</span><span class="headingEndMark"> — </span>Magnesium is required for PTH release and may be required for PTH effect on target organs. Hypomagnesemia can lead to hypocalcemia through the following mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>End-organ unresponsiveness to PTH</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired release of PTH</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired formation of 1,25-dihydroxyvitamin D, likely secondary to both of the above effects</p><p></p><p>Patients with hypomagnesemia present with carpopedal spasm, tetany and/or seizures, muscle weakness, anorexia, and hypokalemia, as well as tachycardia with prolonged QT and PR intervals. Tetany can occur in the absence of hypocalcemia and is thought to be secondary to a depression in the threshold of nerve excitation. Serum concentrations of PTH are typically low or normal but may rise sharply in response to magnesium therapy. Hypomagnesemia can be a primary disorder or secondary to other diseases. (See  <a class="medical medical_review" href="/d/html/848.html" rel="external">"Hypomagnesemia: Clinical manifestations of magnesium depletion"</a>.)</p><p class="headingAnchor" id="H24"><span class="h3">Primary</span><span class="headingEndMark"> — </span>Hypomagnesemia with secondary hypocalcemia (also known as intestinal hypomagnesemia type 1, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F602014&amp;token=87jLzclRwWxNoI%2BQq5Gg7xcLakmtCoUKGsH0VYmZmNSaa2fuBpSdd5VQ6aUYEshQ&amp;TOPIC_ID=5846" target="_blank">MIM #602014</a>) is an autosomal recessive disease caused by mutations in the <em>TRPM6</em> gene (transient receptor potential cation channel, subfamily M, member 6) located at chromosome 9q22 [<a href="#rid89">89,90</a>]. <em>TRPM6</em> is expressed in the intestinal mucosa and the kidney. It encodes for a protein with dual functions, protein kinase, and a calcium and magnesium ion channel. In affected patients, there is an isolated defect of intestinal magnesium absorption with normal renal excretion of magnesium. Although this defect is considered the most severe form of heritable hypomagnesemia, mutations in other genes have been found to be causes of genetic hypomagnesemia  (<a class="graphic graphic_table graphicRef142074" href="/d/graphic/142074.html" rel="external">table 2</a>) [<a href="#rid91">91</a>].</p><p>Patients present in the neonatal period with seizures, hypomagnesemia, and hypocalcemia, and may require large doses of magnesium, up to 20 times the usual daily requirement. These high doses completely correct the hypocalcemia and lead to resolution of symptoms, although they rarely lead to normalization of magnesium concentrations. Oral administration of magnesium can cause diarrhea, which can increase the intestinal loss of magnesium. Early diagnosis and treatment can help avoid sequelae of prolonged seizures caused by hypocalcemia and/or hypomagnesemia.</p><p class="headingAnchor" id="H25"><span class="h3">Secondary</span><span class="headingEndMark"> — </span>Magnesium homeostasis is not hormonally regulated and depends on the balance between intestinal absorption and renal excretion. As a result, the major causes of secondary hypomagnesemia in children are either decreased intake or increased urinary and gastrointestinal losses. Gastrointestinal losses are seen in any disorder associated with acute or chronic diarrhea, steatorrhea, or malabsorption. Renal losses may be because of diuretic use, nephrotoxins (such as aminoglycosides), and renal tubular dysfunction or tubular-interstitial disease [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/d/html/829.html" rel="external">"Hypomagnesemia: Causes of hypomagnesemia"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium homeostasis</strong> – A tightly regulated extracellular ionized calcium concentration promotes cell function and survival and is maintained by an intricate calcium homeostatic system. (See <a class="local">'Normal calcium homeostasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – The primary determinant of symptoms and signs associated with hypocalcemia is the circulating ionized calcium concentration. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal hypocalcemia</strong> – Transient neonatal hypocalcemia is not uncommon, particularly in newborn infants admitted to the neonatal intensive care unit. Contributing factors include those associated with the mother (eg, maternal diabetes mellitus) and the infant (eg, premature), concurrent illnesses, and iatrogenic factors. (See <a class="local">'Neonatal hypocalcemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – A variety of genetic and acquired disorders can cause hypocalcemia  (<a class="graphic graphic_table graphicRef53781" href="/d/graphic/53781.html" rel="external">table 1</a>). The different causes can be clinically distinguished by differences in serum parathyroid hormone (PTH), phosphate, and vitamin D concentrations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low PTH</strong> – Hypoparathyroidism, a major cause of pediatric hypocalcemia, is distinguished clinically by hypocalcemia with low levels of PTH. Hypoparathyroidism is caused by impaired secretion or production of PTH or a defect in the calcium-sensing receptor (CaSR) that regulates PTH secretion  (<a class="graphic graphic_table graphicRef142074" href="/d/graphic/142074.html" rel="external">table 2</a>). (See <a class="local">'Hypocalcemia with low PTH (hypoparathyroidism)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High PTH</strong> – Hypocalcemia with high levels of PTH may be caused by:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Vitamin D deficiency (insufficient dietary vitamin D intake or impaired intestinal absorption, with limited dermal synthesis) (see <a class="local">'Deficient calcium intake or intestinal absorption'</a> above and <a class="local">'Deficient vitamin D intake, intestinal absorption and/or dermal synthesis'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Defects in vitamin D metabolism, including hepatic dysfunction (including drugs that increase cytochrome P450 activity), renal dysfunction, and genetic disorders of vitamin D metabolism (25-hydroxylase deficiency, 1-alpha-hydroxylase deficiency, or mutations in <em>CYP3A4</em>) (see <a class="local">'Defects in vitamin D metabolism'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hereditary resistance to vitamin D (a defect in vitamin D action) (see <a class="local">'Hereditary resistance to vitamin D'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Genetic mutations causing end-organ resistance to PTH in either kidney or bone (pseudohypoparathyroidism [PHP]) (see <a class="local">'End-organ resistance to PTH (pseudohypoparathyroidism)'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – Other important causes of hypocalcemia arise during the course or treatment of medical illnesses. These include hungry bone syndrome (which may be triggered by vitamin D therapy in the setting of severe rickets or after surgical parathyroidectomy); osteopetrosis, sepsis, or acute severe illness; hyperphosphatemia; hypomagnesemia; or certain drugs. (See <a class="local">'Miscellaneous'</a> above.)</p><p></p><p class="headingAnchor" id="H605201726"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges George S Jeha, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gallo S, Comeau K, Sharma A, et al. Redefining normal bone and mineral clinical biochemistry reference intervals for healthy infants in Canada. Clin Biochem 2014; 47:27.</a></li><li><a class="nounderline abstract_t">Maddry JK, Kester A, Heard K. Prolonged hypocalcemia refractory to calcium gluconate after ammonium bifluoride ingestion in a pediatric patient. Am J Emerg Med 2017; 35:378.e1.</a></li><li><a class="nounderline abstract_t">Yatsenko SA, Yatsenko AN, Szigeti K, et al. Interstitial deletion of 10p and atrial septal defect in DiGeorge 2 syndrome. Clin Genet 2004; 66:128.</a></li><li><a class="nounderline abstract_t">Verri A, Maraschio P, Devriendt K, et al. Chromosome 10p deletion in a patient with hypoparathyroidism, severe mental retardation, autism and basal ganglia calcifications. Ann Genet 2004; 47:281.</a></li><li><a class="nounderline abstract_t">Bergman JE, Janssen N, Hoefsloot LH, et al. CHD7 mutations and CHARGE syndrome: the clinical implications of an expanding phenotype. J Med Genet 2011; 48:334.</a></li><li><a class="nounderline abstract_t">Parkinson DB, Thakker RV. A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism. Nat Genet 1992; 1:149.</a></li><li><a class="nounderline abstract_t">Shaw NJ, Haigh D, Lealmann GT, et al. Autosomal recessive hypoparathyroidism with renal insufficiency and developmental delay. Arch Dis Child 1991; 66:1191.</a></li><li><a class="nounderline abstract_t">Sunthornthepvarakul T, Churesigaew S, Ngowngarmratana S. A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J Clin Endocrinol Metab 1999; 84:3792.</a></li><li><a class="nounderline abstract_t">Günther T, Chen ZF, Kim J, et al. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 2000; 406:199.</a></li><li><a class="nounderline abstract_t">Ding C, Buckingham B, Levine MA. Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. J Clin Invest 2001; 108:1215.</a></li><li><a class="nounderline abstract_t">Bilous RW, Murty G, Parkinson DB, et al. Brief report: autosomal dominant familial hypoparathyroidism, sensorineural deafness, and renal dysplasia. N Engl J Med 1992; 327:1069.</a></li><li><a class="nounderline abstract_t">Hasegawa T, Hasegawa Y, Aso T, et al. HDR syndrome (hypoparathyroidism, sensorineural deafness, renal dysplasia) associated with del(10)(p13). Am J Med Genet 1997; 73:416.</a></li><li><a class="nounderline abstract_t">Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature 2000; 406:419.</a></li><li><a class="nounderline abstract_t">Muroya K, Hasegawa T, Ito Y, et al. GATA3 abnormalities and the phenotypic spectrum of HDR syndrome. J Med Genet 2001; 38:374.</a></li><li><a class="nounderline abstract_t">Yumita S, Furukawa Y, Sohn HE, et al. Familial idiopathic hypoparathyroidism and progressive sensorineural deafness. Tohoku J Exp Med 1986; 148:135.</a></li><li><a class="nounderline abstract_t">Barakat AY, D'Albora JB, Martin MM, Jose PA. Familial nephrosis, nerve deafness, and hypoparathyroidism. J Pediatr 1977; 91:61.</a></li><li><a class="nounderline abstract_t">Sanjad SA, Sakati NA, Abu-Osba YK, et al. A new syndrome of congenital hypoparathyroidism, severe growth failure, and dysmorphic features. Arch Dis Child 1991; 66:193.</a></li><li><a class="nounderline abstract_t">Tahseen K, Khan S, Uma R, et al. Kenny-Caffey syndrome in six Bedouin sibships: autosomal recessive inheritance is confirmed. Am J Med Genet 1997; 69:126.</a></li><li><a class="nounderline abstract_t">Bergada I, Schiffrin A, Abu Srair H, et al. Kenny syndrome: description of additional abnormalities and molecular studies. Hum Genet 1988; 80:39.</a></li><li><a class="nounderline abstract_t">Kelly TE, Blanton S, Saif R, et al. Confirmation of the assignment of the Sanjad-Sakati (congenital hypoparathyroidism) syndrome (OMIM 241410) locus to chromosome lq42-43. J Med Genet 2000; 37:63.</a></li><li><a class="nounderline abstract_t">Parvari R, Hershkovitz E, Grossman N, et al. Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. Nat Genet 2002; 32:448.</a></li><li><a class="nounderline abstract_t">Unger S, Górna MW, Le Béchec A, et al. FAM111A mutations result in hypoparathyroidism and impaired skeletal development. Am J Hum Genet 2013; 92:990.</a></li><li><a class="nounderline abstract_t">Thakker RV, Davies KE, Whyte MP, et al. Mapping the gene causing X-linked recessive idiopathic hypoparathyroidism to Xq26-Xq27 by linkage studies. J Clin Invest 1990; 86:40.</a></li><li><a class="nounderline abstract_t">Bowl MR, Nesbit MA, Harding B, et al. An interstitial deletion-insertion involving chromosomes 2p25.3 and Xq27.1, near SOX3, causes X-linked recessive hypoparathyroidism. J Clin Invest 2005; 115:2822.</a></li><li><a class="nounderline abstract_t">Arnold A, Horst SA, Gardella TJ, et al. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest 1990; 86:1084.</a></li><li><a class="nounderline abstract_t">Zupanc ML, Moraes CT, Shanske S, et al. Deletion of mitochondrial DNA in patients with combined features of Kearns-Sayre and MELAS syndromes. Ann Neurol 1991; 29:680.</a></li><li><a class="nounderline abstract_t">Dionisi-Vici C, Garavaglia B, Burlina AB, et al. Hypoparathyroidism in mitochondrial trifunctional protein deficiency. J Pediatr 1996; 129:159.</a></li><li><a class="nounderline abstract_t">Gordon RJ, Levine MA. Genetic Disorders of Parathyroid Development and Function. Endocrinol Metab Clin North Am 2018; 47:809.</a></li><li><a class="nounderline abstract_t">Kifor O, McElduff A, LeBoff MS, et al. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab 2004; 89:548.</a></li><li><a class="nounderline abstract_t">De Sanctis V, Vullo C, Bagni B, Chiccoli L. Hypoparathyroidism in beta-thalassemia major. Clinical and laboratory observations in 24 patients. Acta Haematol 1992; 88:105.</a></li><li><a class="nounderline abstract_t">Carpenter TO, Carnes DL Jr, Anast CS. Hypoparathyroidism in Wilson's disease. N Engl J Med 1983; 309:873.</a></li><li><a class="nounderline abstract_t">Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N Engl J Med 1999; 341:563.</a></li><li><a class="nounderline abstract_t">Clements MR, Johnson L, Fraser DR. A new mechanism for induced vitamin D deficiency in calcium deprivation. Nature 1987; 325:62.</a></li><li><a class="nounderline abstract_t">Ziegler EE, Hollis BW, Nelson SE, Jeter JM. Vitamin D deficiency in breastfed infants in Iowa. Pediatrics 2006; 118:603.</a></li><li><a class="nounderline abstract_t">Thacher TD, Fischer PR, Singh RJ, et al. CYP2R1 Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency. J Clin Endocrinol Metab 2015; 100:E1005.</a></li><li><a class="nounderline abstract_t">Kitanaka S, Takeyama K, Murayama A, et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998; 338:653.</a></li><li><a class="nounderline abstract_t">Yoshida T, Monkawa T, Tenenhouse HS, et al. Two novel 1alpha-hydroxylase mutations in French-Canadians with vitamin D dependency rickets type I1. Kidney Int 1998; 54:1437.</a></li><li><a class="nounderline abstract_t">Wang JT, Lin CJ, Burridge SM, et al. Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families. Am J Hum Genet 1998; 63:1694.</a></li><li><a class="nounderline abstract_t">Scriver CR, Reade TM, DeLuca HF, Hamstra AJ. Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med 1978; 299:976.</a></li><li><a class="nounderline abstract_t">Roizen JD, Li D, O'Lear L, et al. CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest 2018; 128:1913.</a></li><li><a class="nounderline abstract_t">Brooks MH, Bell NH, Love L, et al. Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med 1978; 298:996.</a></li><li><a class="nounderline abstract_t">Labuda M, Fujiwara TM, Ross MV, et al. Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13-14. J Bone Miner Res 1992; 7:1447.</a></li><li><a class="nounderline abstract_t">Baker AR, McDonnell DP, Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A 1988; 85:3294.</a></li><li><a class="nounderline abstract_t">Hughes MR, Malloy PJ, Kieback DG, et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 1988; 242:1702.</a></li><li><a class="nounderline abstract_t">Chen H, Hewison M, Hu B, Adams JS. Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: a cause of vitamin D resistance. Proc Natl Acad Sci U S A 2003; 100:6109.</a></li><li><a class="nounderline abstract_t">Marx SJ, Spiegel AM, Brown EM, et al. A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 1978; 47:1303.</a></li><li><a class="nounderline abstract_t">Balsan S, Garabédian M, Larchet M, et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986; 77:1661.</a></li><li><a class="nounderline abstract_t">Hochberg Z, Tiosano D, Even L. Calcium therapy for calcitriol-resistant rickets. J Pediatr 1992; 121:803.</a></li><li><a class="nounderline abstract_t">Albright F, Burnett CH, Smith PH, Parson W. Pseudo-hypoparathyroidism--an example of 'Seabright-Bantam syndrome': Report of three cases. Endocrinology 1942; 30:922.</a></li><li><a class="nounderline abstract_t">Chase LR, Fedak SA, Aurbach GD. Activation of skeletal adenyl cyclase by parathyroid hormone in vitro. Endocrinology 1969; 84:761.</a></li><li><a class="nounderline abstract_t">Chase LR, Melson GL, Aurbach GD. Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone. J Clin Invest 1969; 48:1832.</a></li><li><a class="nounderline abstract_t">Jüppner H. Molecular Definition of Pseudohypoparathyroidism Variants. J Clin Endocrinol Metab 2021; 106:1541.</a></li><li><a class="nounderline abstract_t">Mantovani G, Bastepe M, Monk D, et al. Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. Horm Res Paediatr 2020; 93:182.</a></li><li><a class="nounderline abstract_t">Bastepe M, Jüppner H. GNAS locus and pseudohypoparathyroidism. Horm Res 2005; 63:65.</a></li><li><a class="nounderline abstract_t">Spiegel AM, Weinstein LS, Shenker A. Abnormalities in G protein-coupled signal transduction pathways in human disease. J Clin Invest 1993; 92:1119.</a></li><li><a class="nounderline abstract_t">Shapira H, Mouallem M, Shapiro MS, et al. Pseudohypoparathyroidism type Ia: two new heterozygous frameshift mutations in exons 5 and 10 of the Gs alpha gene. Hum Genet 1996; 97:73.</a></li><li><a class="nounderline abstract_t">Ahmed SF, Dixon PH, Bonthron DT, et al. GNAS1 mutational analysis in pseudohypoparathyroidism. Clin Endocrinol (Oxf) 1998; 49:525.</a></li><li><a class="nounderline abstract_t">Hayward BE, Kamiya M, Strain L, et al. The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci U S A 1998; 95:10038.</a></li><li><a class="nounderline abstract_t">Farfel Z, Brickman AS, Kaslow HR, et al. Defect of receptor-cyclase coupling protein in psudohypoparathyroidism. N Engl J Med 1980; 303:237.</a></li><li><a class="nounderline abstract_t">Nakamoto JM, Sandstrom AT, Brickman AS, et al. Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsalpha gene mutation. Am J Med Genet 1998; 77:261.</a></li><li><a class="nounderline abstract_t">Farfel Z, Friedman E. Mental deficiency in pseudohypoparathyroidism type I is associated with Ns-protein deficiency. Ann Intern Med 1986; 105:197.</a></li><li><a class="nounderline abstract_t">de Sanctis L, Vai S, Andreo MR, et al. Brachydactyly in 14 genetically characterized pseudohypoparathyroidism type Ia patients. J Clin Endocrinol Metab 2004; 89:1650.</a></li><li><a class="nounderline abstract_t">Levine MA, Downs RW Jr, Moses AM, et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983; 74:545.</a></li><li><a class="nounderline abstract_t">Carlson HE, Brickman AS. Blunted plasma cyclic adenosine monophosphate response to isoproterenol in pseudohypoparathyroidism. J Clin Endocrinol Metab 1983; 56:1323.</a></li><li><a class="nounderline abstract_t">ALBRIGHT F, FORBES AP, HENNEMAN PH. Pseudo-pseudohypoparathyroidism. Trans Assoc Am Physicians 1952; 65:337.</a></li><li><a class="nounderline abstract_t">Fitch N. Albright's hereditary osteodystrophy: a review. Am J Med Genet 1982; 11:11.</a></li><li><a class="nounderline abstract_t">Germain-Lee EL, Groman J, Crane JL, et al. Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab 2003; 88:4059.</a></li><li><a class="nounderline abstract_t">Mantovani G, Maghnie M, Weber G, et al. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type ia: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab 2003; 88:4070.</a></li><li><a class="nounderline abstract_t">Shore EM, Ahn J, Jan de Beur S, et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002; 346:99.</a></li><li><a class="nounderline abstract_t">Murray TM, Rao LG, Wong MM, et al. Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. J Bone Miner Res 1993; 8:83.</a></li><li><a class="nounderline abstract_t">Bastepe M, Fröhlich LF, Hendy GN, et al. Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest 2003; 112:1255.</a></li><li><a class="nounderline abstract_t">Bastepe M, Fröhlich LF, Linglart A, et al. Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat Genet 2005; 37:25.</a></li><li><a class="nounderline abstract_t">Odom J, Bacino CA, Karaviti LP, et al. Intrafamilial phenotypic heterogeneity in siblings with pseudohypoparathyroidism 1B due to maternal STX16 deletion. J Pediatr Endocrinol Metab 2024; 37:84.</a></li><li><a class="nounderline abstract_t">Farfel Z, Brothers VM, Brickman AS, et al. Pseudohypoparathyroidism: inheritance of deficient receptor-cyclase coupling activity. Proc Natl Acad Sci U S A 1981; 78:3098.</a></li><li><a class="nounderline abstract_t">Rodriguez HJ, Villarreal H Jr, Klahr S, Slatopolsky E. Pseudohypoparathyroidism type II: restoration of normal renal responsiveness to parathyroid hormone by calcium administration. J Clin Endocrinol Metab 1974; 39:693.</a></li><li><a class="nounderline abstract_t">Drezner M, Neelon FA, Lebovitz HE. Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal. N Engl J Med 1973; 289:1056.</a></li><li><a class="nounderline abstract_t">Linglart A, Menguy C, Couvineau A, et al. Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance. N Engl J Med 2011; 364:2218.</a></li><li><a class="nounderline abstract_t">Linglart A, Levine MA, Jüppner H. Pseudohypoparathyroidism. Endocrinol Metab Clin North Am 2018; 47:865.</a></li><li><a class="nounderline abstract_t">Michot C, Le Goff C, Goldenberg A, et al. Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis. Am J Hum Genet 2012; 90:740.</a></li><li><a class="nounderline abstract_t">Maass PG, Aydin A, Luft FC, et al. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat Genet 2015; 47:647.</a></li><li><a class="nounderline abstract_t">Subramanian H, Döring F, Kollert S, et al. PTH1R Mutants Found in Patients with Primary Failure of Tooth Eruption Disrupt G-Protein Signaling. PLoS One 2016; 11:e0167033.</a></li><li><a class="nounderline abstract_t">Duchatelet S, Ostergaard E, Cortes D, et al. Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in Eiken and Blomstrand syndromes. Hum Mol Genet 2005; 14:1.</a></li><li><a class="nounderline abstract_t">Thiele S, Mantovani G, Barlier A, et al. From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network. Eur J Endocrinol 2016; 175:P1.</a></li><li><a class="nounderline abstract_t">Kałużna M, Trzeciak I, Ziemnicka K, et al. Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. Orphanet J Rare Dis 2019; 14:275.</a></li><li><a class="nounderline abstract_t">Marraffa JM, Hui A, Stork CM. Severe hyperphosphatemia and hypocalcemia following the rectal administration of a phosphate-containing Fleet pediatric enema. Pediatr Emerg Care 2004; 20:453.</a></li><li><a class="nounderline abstract_t">Wason S, Tiller T, Cunha C. Severe hyperphosphatemia, hypocalcemia, acidosis, and shock in a 5-month-old child following the administration of an adult Fleet enema. Ann Emerg Med 1989; 18:696.</a></li><li><a class="nounderline abstract_t">Gessner BD, Beller M, Middaugh JP, Whitford GM. Acute fluoride poisoning from a public water system. N Engl J Med 1994; 330:95.</a></li><li><a class="nounderline abstract_t">Borkenhagen JF, Connor EL, Stafstrom CE. Neonatal hypocalcemic seizures due to excessive maternal calcium ingestion. Pediatr Neurol 2013; 48:469.</a></li><li><a class="nounderline abstract_t">Walder RY, Shalev H, Brennan TM, et al. Familial hypomagnesemia maps to chromosome 9q, not to the X chromosome: genetic linkage mapping and analysis of a balanced translocation breakpoint. Hum Mol Genet 1997; 6:1491.</a></li><li><a class="nounderline abstract_t">Walder RY, Landau D, Meyer P, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 2002; 31:171.</a></li><li><a class="nounderline abstract_t">Viering DHHM, de Baaij JHF, Walsh SB, et al. Genetic causes of hypomagnesemia, a clinical overview. Pediatr Nephrol 2017; 32:1123.</a></li><li><a class="nounderline abstract_t">van der Made CI, Hoorn EJ, de la Faille R, et al. Hypomagnesemia as First Clinical Manifestation of ADTKD-HNF1B: A Case Series and Literature Review. Am J Nephrol 2015; 42:85.</a></li></ol></div><div id="topicVersionRevision">Topic 5846 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25064025" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Redefining normal bone and mineral clinical biochemistry reference intervals for healthy infants in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27609122" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prolonged hypocalcemia refractory to calcium gluconate after ammonium bifluoride ingestion in a pediatric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15253763" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Interstitial deletion of 10p and atrial septal defect in DiGeorge 2 syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337474" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chromosome 10p deletion in a patient with hypoparathyroidism, severe mental retardation, autism and basal ganglia calcifications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21378379" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : CHD7 mutations and CHARGE syndrome: the clinical implications of an expanding phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1302009" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1719942" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Autosomal recessive hypoparathyroidism with renal insufficiency and developmental delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10523031" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910362" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genetic ablation of parathyroid glands reveals another source of parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602629" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1522843" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Brief report: autosomal dominant familial hypoparathyroidism, sensorineural deafness, and renal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415468" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : HDR syndrome (hypoparathyroidism, sensorineural deafness, renal dysplasia) associated with del(10)(p13).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10935639" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : GATA3 haplo-insufficiency causes human HDR syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389161" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : GATA3 abnormalities and the phenotypic spectrum of HDR syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3961795" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Familial idiopathic hypoparathyroidism and progressive sensorineural deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/874665" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Familial nephrosis, nerve deafness, and hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2001103" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A new syndrome of congenital hypoparathyroidism, severe growth failure, and dysmorphic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9056548" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Kenny-Caffey syndrome in six Bedouin sibships: autosomal recessive inheritance is confirmed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2843457" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Kenny syndrome: description of additional abnormalities and molecular studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10691411" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Confirmation of the assignment of the Sanjad-Sakati (congenital hypoparathyroidism) syndrome (OMIM 241410) locus to chromosome lq42-43.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12389028" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684011" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : FAM111A mutations result in hypoparathyroidism and impaired skeletal development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1973175" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mapping the gene causing X-linked recessive idiopathic hypoparathyroidism to Xq26-Xq27 by linkage studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16167084" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : An interstitial deletion-insertion involving chromosomes 2p25.3 and Xq27.1, near SOX3, causes X-linked recessive hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2212001" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1892371" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Deletion of mitochondrial DNA in patients with combined features of Kearns-Sayre and MELAS syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757579" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hypoparathyroidism in mitochondrial trifunctional protein deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30390815" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Genetic Disorders of Parathyroid Development and Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764760" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1466190" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hypoparathyroidism in beta-thalassemia major. Clinical and laboratory observations in 24 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6888480" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hypoparathyroidism in Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451461" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3025747" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A new mechanism for induced vitamin D deficiency in calcium deprivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16882813" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vitamin D deficiency in breastfed infants in Iowa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25942481" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : CYP2R1 Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486994" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9844119" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Two novel 1alpha-hydroxylase mutations in French-Canadians with vitamin D dependency rickets type I1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9837822" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/308618" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29461981" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : CYP3A4 mutation causes vitamin D-dependent rickets type 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/205789" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1336301" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13-14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2835767" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cloning and expression of full-length cDNA encoding human vitamin D receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2849209" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716975" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: a cause of vitamin D resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/233695" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3009551" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1331389" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Calcium therapy for calcitriol-resistant rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pseudo-hypoparathyroidism--an example of 'Seabright-Bantam syndrome': Report of three cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4304032" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Activation of skeletal adenyl cyclase by parathyroid hormone in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4309802" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33529330" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Molecular Definition of Pseudohypoparathyroidism Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32756064" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15711092" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : GNAS locus and pseudohypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8397218" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Abnormalities in G protein-coupled signal transduction pathways in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557265" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pseudohypoparathyroidism type Ia: two new heterozygous frameshift mutations in exons 5 and 10 of the Gs alpha gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876352" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : GNAS1 mutational analysis in pseudohypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9707596" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6247654" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Defect of receptor-cyclase coupling protein in psudohypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600732" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsalpha gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3089087" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mental deficiency in pseudohypoparathyroidism type I is associated with Ns-protein deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070926" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Brachydactyly in 14 genetically characterized pseudohypoparathyroidism type Ia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6301273" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6302127" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Blunted plasma cyclic adenosine monophosphate response to isoproterenol in pseudohypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13005676" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pseudo-pseudohypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6278930" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Albright's hereditary osteodystrophy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970262" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970263" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type ia: new evidence for imprinting of the Gs alpha gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11784876" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8427051" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561710" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592469" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38095637" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intrafamilial phenotypic heterogeneity in siblings with pseudohypoparathyroidism 1B due to maternal STX16 deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6265935" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pseudohypoparathyroidism: inheritance of deficient receptor-cyclase coupling activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4370302" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pseudohypoparathyroidism type II: restoration of normal renal responsiveness to parathyroid hormone by calcium administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4355058" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21651393" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30390819" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pseudohypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22464250" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25961942" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : PDE3A mutations cause autosomal dominant hypertension with brachydactyly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27898723" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : PTH1R Mutants Found in Patients with Primary Failure of Tooth Eruption Disrupt G-Protein Signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15525660" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in Eiken and Blomstrand syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27401862" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31791361" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15232246" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Severe hyperphosphatemia and hypocalcemia following the rectal administration of a phosphate-containing Fleet pediatric enema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729698" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Severe hyperphosphatemia, hypocalcemia, acidosis, and shock in a 5-month-old child following the administration of an adult Fleet enema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8259189" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Acute fluoride poisoning from a public water system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23668874" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Neonatal hypocalcemic seizures due to excessive maternal calcium ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285786" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Familial hypomagnesemia maps to chromosome 9q, not to the X chromosome: genetic linkage mapping and analysis of a balanced translocation breakpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032570" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27234911" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Genetic causes of hypomagnesemia, a clinical overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26340261" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Hypomagnesemia as First Clinical Manifestation of ADTKD-HNF1B: A Case Series and Literature Review.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
